Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Date:8/8/2013

have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer.  Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial completion and design, statements regarding the potential benefits and potential development of our product candidates and statements regarding our future expenses and the use and adequacy of our cash resources. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that our product candidates will not demonstrate the hypothesized or expected benefits, the risk of delays in our expected clinical trials, the risk that new developments in the rapidly evolving cancer therapy landscape require changes in our clinical trial plans or limit the potential benefits of our product candidates and the other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including the Company's Annual Rep
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
3. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
4. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
5. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
6. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
7. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
8. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
9. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
10. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
11. Auxilium Pharmaceuticals, Inc, Announces Second Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014  Medical Science Liaisons play a large ... between the medical device industry and key stakeholders, the ... coming years as the device industry relies on them ... research by benchmarking firm, Best Practices, LLC, one area ... edge is by harnessing new technology to enable education. ...
(Date:12/22/2014)... , Dec. 22, 2014   TRU-D SmartUVC ... no-touch UV disinfection robot, announced today that the General ... contract through November 2019.   This newly ... engage all levels of government purchasers, including Department of ... well as Homeland Security contacts purchasing solutions for the ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today issued the following open letter to shareholders ... Dr. Med. Sc. Dear RXi Shareholders, ... number of inaccurate statements posted on certain social ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... BETHESDA, Md. , Aug. 2 /PRNewswire-Asia/ -- Chindex International, Inc.,("Chindex") ... of Western,healthcare products and services in the People,s Republic of China ... results on Monday, August 9, 2010 , before the market opens.,Management ... day to discuss,financial results. , , ...
... PALO ALTO, Calif. , Aug. 2 Jazz Pharmaceuticals, Inc. (Nasdaq: ... 2010 financial results on Tuesday, August 10, 2010 .  Jazz Pharmaceuticals will host ... as to discuss financial results and guidance, on August 10, 2010 , at ... , , ...
Cached Medicine Technology:Chindex International to Report First Quarter 2011 Financial Results 2Jazz Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 10 2
(Date:12/26/2014)... Plugin and template developers from Pixel Film ... Final Cut Pro X. , “TransPack Volume 5 gives users ... off an industry professional look” Said Christina Austin, CEO of ... Volume 5, a new level of professionalism will become the ... 50 Final Cut Pro X transitions featuring organic animations. Choose ...
(Date:12/26/2014)... FL (PRWEB) December 26, 2014 India ... health insurance in the USA, announced today a new ... assist members in choosing the right plan for their ... the complexity out of the selection process when choosing ... by age group with only a few clicks. Many ...
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a ... producing and marketing of a series of induction heating ... new series of induction brazing equipments . , ... induction brazing refers to the joining of two ... heat. The manager says that there are fundamental differences ...
(Date:12/25/2014)... 26, 2014 The microscopy market ... 7.2% to reach $5,756.0 million by 2019. Optical ... market. The electron microscopes product segment is expected ... period. , Rising focus on nanotechnology, technological advancements, ... the microscopy market. , Get Full Copy of ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 ... BambooFlooringChina.com combines beauty, strength and durability. Today, the ... promotion, which is valid until Jan. 30, 2015. ... grain of traditional hardwood. BambooFlooringChina.com is a well-known ... help consumers worldwide to find a reliable bamboo ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2
... but resistant disease can develop in first year, study ... antiretroviral drug nevirapine may help prevent babies of HIV-positive ... also greatly increases the odds of developing drug-resistant HIV ... life, a new study finds. , Still, the researchers ...
... vision especially if you are named Barack Hussein Obama. , ... ... Presidential Inauguration on Tuesday, January 20, Khanna Institute of LASIK ... named "Barack Hussein Obama". "This is a historic moment in American ...
... of Atlanta School of Massage, taking the National Certification Examination for ... than twenty points higher than the national average. , ... ... School of Massage (atlantaschoolofmassage.com), taking the National Certification Examination for Therapeutic ...
... Johnson Will Commence Subsequent Offering Period NEW BRUNSWICK, N.J., Jan. ... today announced that the initial tender offer, through its wholly ... of common stock of Mentor Corporation (NYSE: MNT ... 2009, and was not extended.The depositary for the tender offer ...
... Amos and Keebler peanut butter cookies; FDA asks more ... stands at 452 sick in 43 states and 1 ... 16 (HealthDay News) -- Cereal giant Kellogg recalled 16 ... officials expanded their investigation into peanut products possibly contaminated ...
... BATTLE CREEK, Mich., Jan. 16 Kellogg Company,today ... Keebler(R) branded,Peanut Butter Sandwich Crackers and select snack-size ... Soft Batch Homestyle Peanut Butter,Cookies because the products ... other products are involved in this recall. , ...
Cached Medicine News:Health News:HIV Drug a Double-Edged Sword for Infants 2Health News:LASIK Surgery for "Barack Hussein Obama" 2Health News:Atlanta School of Massage Grads Beat National Test Scores By Wide Margin 2Health News:Johnson & Johnson Completes Initial Tender Offer for Mentor Corporation with 92.9% of Shares Tendered 2Health News:Johnson & Johnson Completes Initial Tender Offer for Mentor Corporation with 92.9% of Shares Tendered 3Health News:Kellogg Recalls 16 Products as Salmonella Probe Widens 2Health News:Kellogg Recalls 16 Products as Salmonella Probe Widens 3Health News:Kellogg Recalls 16 Products as Salmonella Probe Widens 4Health News:Kellogg Company Announces Voluntary Nationwide Recall of Austin(R) and Keebler(R) Branded Peanut Butter Sandwich Crackers and Select Snack-Size Packs of Famous Amos(R) and Keebler(R) Soft Batch Peanut Butter Cookies Because of Possible Health Risk 2Health News:Kellogg Company Announces Voluntary Nationwide Recall of Austin(R) and Keebler(R) Branded Peanut Butter Sandwich Crackers and Select Snack-Size Packs of Famous Amos(R) and Keebler(R) Soft Batch Peanut Butter Cookies Because of Possible Health Risk 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: